Treatment Set TS332080 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Acer Negundo Pollen; Poa Pratensis Pollen; Cynodon Dactylon Pollen; Sorghum Halepense Pollen; Fraxinus Americana Pollen; Quercus Alba Pollen; Populus Deltoides Pollen.
| Product ID | 49288-0702_89f9e682-acd9-4cc7-982d-c32f69b33b07 |
| NDC | 49288-0702 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Treatment Set TS332080 |
| Generic Name | Treatment Set Ts332080 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ACER NEGUNDO POLLEN; POA PRATENSIS POLLEN; CYNODON DACTYLON POLLEN; SORGHUM HALEPENSE POLLEN; FRAXINUS AMERICANA POLLEN; QUERCUS ALBA POLLEN; POPULUS DELTOIDES POLLEN |
| Active Ingredient Strength | 0 g/mL; [BAU]/mL; [BAU]/mL; g/mL; g/mL; g/mL; g/mL |
| Pharm Classes | Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-10-21 |
| Ingredient | Strength |
|---|---|
| ACER NEGUNDO POLLEN | .00033 g/mL |